News
Videos
Conferences
Events
Resources
Subscribe

Opinion|Videos|November 15, 2023

The Role of the HER2 Receptor in Breast Cancer

Author(s)Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, introduces the role of HER2 as a breast cancer cell growth receptor and explains HER2-positive versus HER2-negative.

Episodes in this series

EP. 1 The Role of the HER2 Receptor in Breast Cancer

EP. 1 The Role of the HER2 Receptor in Breast Cancer

EP. 2 Necessary Tests After a Diagnosis of Breast Cancer

EP. 2 Necessary Tests After a Diagnosis of Breast Cancer

EP. 3 Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

EP. 3 Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

EP. 4 Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist

EP. 4 Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist

EP. 5 Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

EP. 5 Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

EP. 6 Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

EP. 6 Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

EP. 7 Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

EP. 7 Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

EP. 8 How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

EP. 8 How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

EP. 9 Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

EP. 9 Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

EP. 10 Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP. 10 Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP. 11 Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP. 11 Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Newsletter

Stay up to date on cancer updates, research and education

Related Content

"FDA" text.

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

December 15th 2025

Image of Debbie.

Accepting That You Are Changed by Cancer

ByDebbie Legault

December 15th 2025

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower: © stock.adobe.com.

Fertility Decisions Influenced by Age and Parental Status in Premenopausal Breast Cancer

December 12th 2025

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer

ByJason Broderick

December 12th 2025

image of woman.

HRT Use Does Not Raise Breast Cancer Risk in BRCA Carriers

December 12th 2025

Trending on CURE

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey

Light the Night and Survivorship: The Importance of Remembrance

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

© 2025 MJH Life Sciences^®

All rights reserved.